Quickly find freely available drug and population models in our PBPK model repository.
The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.
You can use a suffix operator (*) as the placeholder for end of a term. The query must start with at least one alphanumeric character before the suffix operator. E.g., Rifam* will get you “Rifampicin” and “Rifampin”. For more advanced searching tips click here.
The V21 RES-Levonorgestrel file has been developed as a substrate of CYP3A4. The file was developed to capture the pharmacokinetics after administration of Levonorgestrel alone or in combination with Ethinyl Estradiol. A workspace and performance summary are available. Levonorgestrel is known to bind to the plasma protein Sex Hormone Binding Globulin and this has been captured in the file by utilising the other protein option in the population.
The RES-Benzylpenicillin file was primarily developed as a substrate of renal OAT3 transport. This document provides: 1. Examples of model performance 2. A summary of the key pharmacokinetic features of benzylpenicillin considered within the model.
Three compound files for adults and 3 files for paediatrics are available for the parent compounds, Valproic Acid, reflecting the inputs required for EC tablets, tablets, and capsules, respectively. A compound file for the metabolite, 4-ene-Valproid Acid is available too. Details on the model assumptions and verification in V21R1 are available in the corresponding reference (DOI: 10.1002/psp4.13045) and supplement material on the journal (CPT: Pharmacometrics & Systems Pharmacology) website.
Brand Name(s) include: Thorazine, Largactil, Ormazine
Indication: Schizophrenia, manic-depression
Drug Class: Conventional anitpsychotic
Date Updated: March 2024
|
Absorption Model |
|
|
Volume of Distribution |
|
|
Route of Elimination |
|
|
Perpetrator DDI |
|
|
Validation |
|
|
Limitations |
|
|
35 |